Pacira BioSciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M |
| Cost of revenue | $149.7M | $170.4M | $184.7M | $199.3M | $140.3M |
| Selling, general & administrative | $368.8M | $294.1M | $269.4M | $254.5M | $199.3M |
| Research and development | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M |
| Interest expense | $17.4M | $16.6M | $20.3M | $40.0M | $31.8M |
| Pretax income | $16.9M | -$63.1M | $61.7M | $13.3M | $56.4M |
| Income tax expense | $9.8M | $36.5M | $19.7M | -$2.6M | $14.4M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M |
| Balance Sheet | |||||
| Cash and equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M |
| Current assets | $548.0M | $745.1M | $510.0M | $498.3M | $866.0M |
| Total assets | $1.3B | $1.6B | $1.6B | $1.7B | $2.1B |
| Current liabilities | $120.6M | $309.9M | $97.4M | $147.8M | $521.1M |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.3B |
| Stockholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M |
| Cash Flow Statement | |||||
| Cash from operations | $152.0M | $189.4M | $154.6M | $145.3M | $125.7M |
| Depreciation and amortization | $91.0M | $78.8M | $75.6M | $91.5M | $28.5M |
| Stock-based compensation | $57.5M | $51.2M | $47.9M | $48.1M | $42.2M |
| Capital expenditure | $15.3M | $10.6M | $15.2M | $30.1M | $45.9M |
| Free cash flow | $136.7M | $178.8M | $139.5M | $115.2M | $79.9M |
| Share repurchases | $148.3M | $25.0M | $0 | $0 | — |
| Impairments | $0 | $163.2M | $0 | $0 | $0 |
Shares outstanding 39.3M · Free float 61.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.